文献速递淋巴瘤

外周T细胞淋巴瘤与NK/T细胞淋巴瘤中PIK3通路的评估

Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
PubMed 文献 · Br J Haematol · 2020-01-31

该研究通过免疫组化分析88例外周T细胞淋巴瘤(PTCL)和NK/T细胞淋巴瘤(NKTCL)样本中PIK3各亚型及PTEN的表达,发现所有样本均高表达PIK3亚型,其中PIK3α高表达与不良生存显著相关。 pan-class I抑制剂copanlisib可抑制AKT、4E-BP-1和STAT3磷酸化,诱导细胞周期阻滞并抑制肿瘤生长,提示同时靶向PIK3α和δ可能是有前景的治疗策略。

要点

  • PTCL和NKTCL样本普遍高表达PIK3亚型。
  • PIK3α高表达与更差生存显著相关,且经年龄、IPI评分和蒽环类一线化疗调整后仍显著。
  • Copanlisib可抑制PIK3通路下游信号并抑制肿瘤生长。

核心结论

  • 靶向PIK3通路,尤其是同时抑制PIK3α和δ,可能是治疗PTCL和NKTCL的有前景策略。

研究设计与样本

  • 研究采用免疫组化方法分析88例PTCL和NKTCL样本中PIK3α、PIK3β、PIK3γ、PIK3δ及PTEN的表达。
  • 体外和体内实验评估copanlisib对PIK3通路及肿瘤生长的影响。

主要发现

  • 所有PTCL和NKTCL样本均显示PIK3亚型高表达。
  • PIK3α高表达与不良生存显著相关,即使调整年龄、国际预后指数(IPI)评分和一线蒽环类化疗后仍显著。
  • Copanlisib有效抑制AKT、4E-BP-1和STAT3磷酸化,导致G0/G1细胞周期阻滞,并在体外和体内抑制肿瘤细胞生长。

临床怎么用

  • PIK3α表达可能作为PTCL和NKTCL的预后标志物。
  • Copanlisib(同时抑制PIK3α和δ)值得在PTCL和NKTCL中开展临床测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphomas (PTCL) and natural killer (NK)/T-cell lymphomas (NKTCL) are a heterogeneous group of aggressive malignancies with dismal outcomes and limited treatment options. While the phosphatidylinositol 3-kinase (PIK3) pathway has been shown to be highly activated in many B-cell lymphomas, its therapeutic relevance in PTCL and NKTCL remains unclear. The aim of this study is to investigate the expression of PIK3 and phosphatase and tensin homolog (PTEN) in these subtypes of lymphoma and to identify potential therapeutic targets for clinical testing. Therefore, the expression of PIK3α, PIK3β, PIK3γ, PIK3δ and PTEN was analyzed in 88 cases of PTCL and NKTCL samples by immunohistochemistry. All PTCL and NKTCL samples demonstrated high expression of PIK3 isoforms. In particular, high PIK3α expression was significantly associated with poor survival, even after adjustment for age, International Prognostic Index (IPI) score and anthracycline-based chemotherapy in first line. Notably, copanlisib, a pan-class I inhibitor with predominant activities towards PIK3α and PIK3δ isoforms, effectively inhibited phosphorylation of AKT, 4E-BP-1 and STAT3, causing G0 /G1 cell cycle arrest and resulting in suppression of tumour cell growth in vitro and in vivo. This study provides evidence that targeting the PIK3 pathway, particularly simultaneous inhibition of PIK3α and δ, could be a promising approach for the treatment of PTCL and NKTCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huang D, Song TL, Nairismägi ML, et al. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma. Br J Haematol. 2020. PMID: 32004387. doi:10.1111/bjh.16435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。